we two joining clinical today. is treat of support to you, that diseases rare cause Naomi. everyone mission are our mission. important Thank At the Fulcrum, you advancing morning, assets thank and us Good stage that and root for genetic
therapy be untreated program Phase to positioned for population. first FSHD X a our that The an is patient is first-to-market
broadly HbF our is can potential with the oral outcomes daily be inducer, hemoglobinopathies The for disease once therapy diseases. sickle the other that first improve these program to cell a and second for
an with I'll shows promise in that our HbF in great these disease update inducer the in oral first mechanism broadly cell treatment unmet made populations. sickle only VOC for XXXX been consists The target start shown have programs that critical significant the progress cell of hemoglobinopathies. across and select clinical of sickle needs has on addressing We quarter. HbF FTX-XXXX, other events, disease. patient only these outcomes including and is acute to current syndrome. symptoms fatigue, improve pain, chest anemia, landscape therapies
June from X induce we from gram at of January, positioned HbF in current through As trial is agent place plan to had HbF, ongoing the that Xb Hematology XXXX share the the only development we our believe in announced dosing a dosed first Association induction in dose European In million Congress landscape. emerging starting initial uniquely to taking with cohort that data Phase patient potential we and including the We the of measures milligrams. at XX. X X our
update will next living cohort after share protein We we months. with first protein induction quarter, erythropoiesis, EHA. people would of anticipate protein from cohort three signs the in Notably, have maximal the and along Based HbF be with on five process open receiving of other HbF this treatment to at trial the to disease potentially at with data induction data month Phase this mechanisms, sickle seeing cell induction Xb the more of details also XXXX. one to plan we'll on in the and that at look dosing
is concept As increases provide study over an early a HbF. our of designed that proof Phase of trial a range Xb XXXX is doses to evidence reminder, at
for a have this cell of people HbF of to evidence concept HbF of as proof consider initial X% disease levels with XX%. For this data, Typically, we program. would induction sickle
result in These of cell individuals no that people with of These of as HbF, persistence subset fetal condition disease. known a a to However, elevated and cell symptoms little hereditary clinical hemoglobin. additional clearly levels mutations have this data in data, sickle understood sickle have demonstrates an consistently of trait to HbF HbF that X% and for care. XX% state patients standard beyond be increase used outcomes. levels that would well be absolute improve KOLs Based baseline in baseline on of increases level transformative as would genetic
that and can give volunteers Our in believe achieve our to we these XX% robust healthy life-changing preclinical data people absolute disease. for with that reason sickle to increases data Phase will us be X% cell X
second of a half remaining allows advancing in cell in to populations and non-sickle that We the beta-thalassemia execute XXXX the believe to expeditiously focus well. be other year. timing plans trial patient the are anticipated in in hemoglobinopathies. in morning, could committed hemoglobinopathies developing these the XXXX updated of This transformative development initiation us trial we This timing sickle as a while hemoglobinopathies, including our well-positioned also successfully shift the of to cell to therapy for other disease, on we
dosing to on common for muscular track Phase losmapimod, Phase our second quarter. most which candidate to is our of in REACH on X Moving remain patients begin this FSHD, the form We dystrophy. X trial
primary Dystrophy some be as adults trial to and evaluate the X in potential As a in and FSHD and losmapimod clinical the with reachable Association regulators functions. Clinical that REACH same discuss progression FSHD, these focus a Based In debilitating on progression key data REACH. measure to closer benefit, trial, hosted presented Xb data quantitative therapy people Muscular or Losmapimod hosted Society, of can the quantitative community. show disease REACH to unmet ReDUXX disease benefit and is and with relevant the is on RWS. Phase from is is FSHD KOLs first a improved notably key step believe endpoint. month, XX a of treatment aspects event based weeks, and design on compared to-date, demonstrating that one the as in in aligned the key a trial first-to-market even on landmark timeframe. RWS delivering for in insights, the or potentially we clinical that learnings to the measures That the leading of of design design brings we progression, Phase with us function the trial measurable a Together a XX REACH supporting and FSHD, patient the it placebo ReDUXX positioned a in from life-changing and we we on disease. this Conference. to slow need cases, most The Scientific with FSHD we will of we the study for to ever over also that RWS that week therapy function period reflects severe with RWS the disease has at with to measure the stop workspace of March, sensitive with webinar REACH an data
Academy we the April, presented supporting clinical of as at of American of Neurology data in design the Annual well losmapimod potential the as Meeting, Additionally, REACH.
measures We for lose and have in made are marks disease that, else urgent community. progression. as for we improvement milestone tolerability the of losmapimod. FSHD an is important from with the strength, data proud the advances. or an losmapimod's delayed of need stop last no in FSHD The for Fulcrum function. year by with reported progress also is and we There do showing for disease demonstrate progression the mobility function, FSHD drug that database. and potential There supported can People an and safety independence, extensive approved drugs that nothing clinic. Losmapimod exactly ReDUXX a currently REACH slow to and are
REACH, we've with the progress initiating addition in also our In to for preparing significant commercial gains of launch. made potential
have we of success, formulation for losmapimod. needed progressed infrastructure internal the building Beyond commercial
rapidly first identify on year, quality by diseases, pipeline. development remain Additionally, XXXX it backbone the well and to losmapimod novel allowed IND we power root the engine the are us fourth our the of the of nominate and care losmapimod, the quarter FulcrumSeek, as that of end the submit our and care targets our of end to our engage our genetic as FulcrumSeek ongoing providers be maximal We to collaborations expectations. to candidate continue of has will continues to track this XXXX. company. testament patients, product modulate partners potential meet of and communities rare by what to a with innovation cause to has the high and power ensure Fulcrum's next
advance establish Fulcrum to we to are through therapies foundation a life-changing as and potentially into I'll Judy. two development, it As clinical rare over company well-positioned turn pipeline, we while supported runway a disease XXXX. our strong leading extending financial With that, cash a with
